Philadelphia Fight   Report issue

Academic/Hospital Phase 1 Phase 2 Phase 4
Founded: Philadelphia PA United States (1990)

Organization Overview

First Clinical Trial
2008
NCT00594880
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2018

Timeline

NOW
  • Now

Alternative names

Jonathan Lax Immune Disorders Clinic- Philadelphia FIGHT | Philadelphia Fight

Active Ingredients

Drugs in Phase 4 Trials (2)

emtricitabine (emtriva) (1 trial)

tenofovir (viread) (1 trial)

Drugs in Phase 2 Trials (1)

interferon alpha-2b (Intron-A) (2 trials)

Drugs in Phase 1 Trials (2)

3bnc117 (1 trial)

vrc-hivmab080-00-ab (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Communicable Diseases (Phase 2)

Infections (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 3
  • # of Trial APIs: 5